Sanofi Acquires Global Rights to RG-012, Investigational Alport Syndrome Therapy
Under a restructured agreement with Regulus Therapeutics, Sanofi Genzyme now has sole responsibility for the development and marketing of the investigational therapy RG-012, currently under evaluation for the treatment of Alport syndrome. The amendment to the prior collaboration agreement between Sanofi and Regulus, RG-012’s initial developer, gives…